Tags

Type your tag names separated by a space and hit enter

Management of alcoholic liver disease.
Clin Liver Dis 2009; 13(2):267-75CL

Abstract

Understanding alcohol addiction and abstinence is key to treating alcoholic liver disease, since abstinence leads to improvement in all forms of alcoholic liver damage. Although pharmacotherapy for alcoholism, using agents such as naltrexone, acamprosate, topiramate, and baclofen, is an exciting field, few studies have included patients with liver disease or cirrhosis. To treat alcoholic liver injury, corticosteroids have become the standard of care in patients with severe alcoholic hepatitis. In contrast, the role of pharmacotherapy to treat alcoholic fibrosis is unclear, with failure to observe a benefit in randomized, placebo-controlled clinical trials of colchicine, S-adenosylmethionine (SAMe), or phosphatidylcholine. Liver transplantation remains an option in selected patients with life-threatening alcoholic liver disease.

Authors+Show Affiliations

Section of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, H6/516 CSC, 600 Highland Avenue, Madison, WI 53792, USA. mrl@medicine.wisc.edu

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19442918

Citation

Lucey, Michael R.. "Management of Alcoholic Liver Disease." Clinics in Liver Disease, vol. 13, no. 2, 2009, pp. 267-75.
Lucey MR. Management of alcoholic liver disease. Clin Liver Dis. 2009;13(2):267-75.
Lucey, M. R. (2009). Management of alcoholic liver disease. Clinics in Liver Disease, 13(2), pp. 267-75. doi:10.1016/j.cld.2009.02.003.
Lucey MR. Management of Alcoholic Liver Disease. Clin Liver Dis. 2009;13(2):267-75. PubMed PMID: 19442918.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of alcoholic liver disease. A1 - Lucey,Michael R, PY - 2009/5/16/entrez PY - 2009/5/16/pubmed PY - 2009/8/12/medline SP - 267 EP - 75 JF - Clinics in liver disease JO - Clin Liver Dis VL - 13 IS - 2 N2 - Understanding alcohol addiction and abstinence is key to treating alcoholic liver disease, since abstinence leads to improvement in all forms of alcoholic liver damage. Although pharmacotherapy for alcoholism, using agents such as naltrexone, acamprosate, topiramate, and baclofen, is an exciting field, few studies have included patients with liver disease or cirrhosis. To treat alcoholic liver injury, corticosteroids have become the standard of care in patients with severe alcoholic hepatitis. In contrast, the role of pharmacotherapy to treat alcoholic fibrosis is unclear, with failure to observe a benefit in randomized, placebo-controlled clinical trials of colchicine, S-adenosylmethionine (SAMe), or phosphatidylcholine. Liver transplantation remains an option in selected patients with life-threatening alcoholic liver disease. SN - 1557-8224 UR - https://www.unboundmedicine.com/medline/citation/19442918/Management_of_alcoholic_liver_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1089-3261(09)00005-1 DB - PRIME DP - Unbound Medicine ER -